Skip to content

Press

Portfolio-Press Releases
Cerevance Achieves Second Milestone in Research Collaboration with Merck
October 8, 2024 Oct 8, 2024
Portfolio-Press Releases
ReCode Announces Two Key Additions to Scientific Advisory Board
October 1, 2024 Oct 1, 2024
Portfolio-Press Releases
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
September 26, 2024 Sep 26, 2024
Portfolio-Press Releases
Cerevance Appoints Sagar Vaidya, M.D. Ph.D., as Chief Medical Officer
August 12, 2024 Aug 12, 2024
Portfolio-Press Releases
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
June 27, 2024 Jun 27, 2024
Portfolio-Press Releases
New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction
June 13, 2024 Jun 13, 2024
Portfolio-Press Releases
ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors
May 13, 2024 May 13, 2024
Portfolio-Press Releases
Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer
May 13, 2024 May 13, 2024
Portfolio-Press Releases
Cerevance Achieves First Milestone in Research Collaboration with Merck
May 2, 2024 May 2, 2024
Portfolio-Press Releases
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
April 25, 2024 Apr 25, 2024